An interventional study of Wolbachia-infected Aedes aegypti mosquitoes and standard practice dengue control in Dengue, Zika Virus Infection and Chikungunya Fever, sponsored by Gadjah Mada University. Terminated at 1 site in Indonesia. Open to participants aged 3 Years to 45 Years. Per ClinicalTrials.gov, last updated 2020-06-09.
Sponsored by Gadjah Mada University · Not applicable, Interventional, and Prevention
This cluster randomised trial will evaluate the efficacy of Wolbachia-infected Aedes aegytpi mosquitoes in reducing dengue cases in Yogyakarta City, Indonesia
Primary objective:
To assess the efficacy of community-based deployments of Wolbachia-infected Aedes aegypti mosquitoes in reducing the incidence of symptomatic, virologically-confirmed dengue cases of any severity in Yogyakarta residents aged 3-45 years in release areas, relative to non-release areas.
Secondary objectives:
Study setting:
The study will be conducted in Yogyakarta City and Bantul District, both located in the province of Yogyakarta Special Region, Indonesia.The study site is 26 km2 in size, including 24 km2 within Yogyakarta City, and 2km2 in the adjacent Bantul District. The total population of the study area is approximately 350,000.
Study design:
A cluster randomised trial with a test-negative design will be conducted. The study site will be divided into 24 clusters. The intervention will be allocated using constrained block randomisation with a parallel 1:1 assignment of intervention and control.
The intervention is the deployment of Wolbachia-infected Aedes aegypti mosquitoes. Wolbachia deployments will be conducted in intervention clusters with the aim of achieving Wolbachia establishment (>80% mean Wolbachia prevalence in trapped mosquitoes) throughout intervention areas within one year.
The impact of Wolbachia deployments on dengue incidence will be assessed by comparing the exposure distribution (probability of living in a Wolbachia-treated area) among virologically-confirmed dengue cases presenting to a network of public primary clinics (Puskesmas), against the exposure distribution among patients with febrile illness of non-arboviral aetiology presenting to the same network of clinics in the same temporal windows. Dengue cases and arbovirus-negative controls will be sampled concurrently from within the population of patients presenting with febrile illness to the study clinic network, with case or control status classified retrospectively based on the results of laboratory diagnostic testing.
A re-estimation of sample size requirements was conducted in January 2019 after one year of recruitment. The initial power calculation used 1000 dengue cases and 4000 non-dengue controls allocated to each cluster based on historical proportions of dengue cases and other febrile illnesses, assuming no variation in the proportion of cases by cluster. This method was found to overestimate power for small samples by not taking into account randomness in the sampling. The sample size re-estimation included power estimates for 200, 400, 600, 800 and 1000 dengue cases with 4 times as many controls allocated to each cluster by sampling from a multinomial distribution, which incorporated added randomness by allowing the proportion of cases allocated to each cluster to vary across simulations. The re-estimation found that 400 dengue cases plus four times as many controls would be sufficient to detect a 50% reduction in dengue incidence with 80% power.
Participant selection:
Participants will be enrolled from within the population of patients presenting with undifferentiated fever of 1-4 days duration, to one of the participating local health clinics (Puskesmas).
All patients meeting the inclusion criteria will be invited to participate in the study. From baseline historical data we expect approximately 5000 participants per annum to be enrolled.
Enrolment will continue for up to 36 months.
Analysis plan:
Permutation tests and standard regression models will be used to estimate the relative risk of dengue in Wolbachia-treated versus untreated clusters, accounting for the non-independence of study participants resident in the same intervention cluster, and temporal matching of dengue cases and test-negative controls.
The intention-to-treat analysis will consider Wolbachia exposure as binary depending on the allocation of the cluster of residence.
The per-protocol analysis will consider Wolbachia exposure as a continuous weighted index based on Wolbachia prevalence in trapped mosquitoes in the cluster of residence, either with or without weighting for time spent in other clusters visited during the ten days prior to illness onset.
279 studies on the registry are indexed under Dengue; 45 are open to participants now.
This study's enrollment of 8,173 is above the median of 123 across 195 interventional studies indexed under Dengue.
Browse Dengue studies →Gadjah Mada University is the lead sponsor of 62 studies on the registry; 20 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Deployment of Wolbachia-infected Aedes aegypti mosquitoes
Biological: Wolbachia-infected Aedes aegypti mosquitoes · Other: standard practice dengue control
Standard practice dengue control activities
Other: standard practice dengue control
Deployment of Wolbachia-infected Aedes aegypti mosquitoes
standard practice dengue control activities conducted by dengue control program
Relative risk of dengue in Wolbachia-treated versus untreated clusters
Symptomatic, virologically-confirmed dengue virus (DENV) infection of any severity
Time frame: Up to 36 months participant enrolment
Relative risk of serotype-specific dengue in Wolbachia-treated versus untreated clusters
Symptomatic, virologically-confirmed serotype-specific DENV infection of any severity.
Time frame: Up to 36 months participant enrolment
Relative risk of Zika in Wolbachia-treated versus untreated clusters
Symptomatic, virologically-confirmed Zika virus (ZIKV) infection of any severity.
Time frame: Up to 36 months participant enrolment
Relative risk of Chikungunya in Wolbachia-treated versus untreated clusters
Symptomatic, virologically-confirmed Chikungunya virus (CHIKV) infection of any severity.
Time frame: Up to 36 months participant enrolment
Documents are hosted by the registry — open the source record to download them.
Plan to share: Undecided
This study is terminated, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Gadjah Mada University